LDL CHOLESTEROL REDUCTION IN ELDERLY PATIENTS WITH THE PCSK9 MONOCLONAL ANTIBODY EVOLOCUMAB (AMG 145): A POOLED ANALYSIS OF 1779 PATIENTS IN PHASE 2, 3 AND OPEN LABEL EXTENSION STUDIES

Autor:	Ransi Somaratne, Michael J. Koren, Erik Stroes, Narimon Honarpour, Mary Elliott, Bobby Khan, Scott M. Wasserman, Robert Rosenson
Rok vydání:	2015
Předmět:	Oncology Ldl cholesterol medicine.medical_specialty business.industry medicine.drug_class PCSK9 Monoclonal antibody Evolocumab Pooled analysis Internal medicine Immunology Medicine Lipid lowering Risk factor Open label Cardiology and Cardiovascular Medicine business
Zdroj:	Journal of the American College of Cardiology. 65:A1366
ISSN:	0735-1097
Popis:	Advanced age is a highly prevalent and arguably, the strongest risk factor for CVD. Though elderly patients derive benefits from LDL-C reduction, clinicians remain wary about aggressive lipid lowering in this group. Evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, has demonstrated
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc297bf7882fc6391374deff21527274 https://doi.org/10.1016/s0735-1097(15)61366-3 Zobrazit plný text záznamu